News >

Infusion-Schedule Challenges Halt Exploration of Carfilzomib/Ibrutinib in R/R MCL

Jessica Hergert
Published: Tuesday, Mar 24, 2020

Hun Ju Lee, MD, associate professor of medicine, Department of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center

Hun Ju Lee, MD

Findings from a recent phase I study show the combination of carfilzomib (Kyprolis) and ibrutinib (Imbruvica) is well tolerated among patients with relapsed/refractory mantle cell lymphoma (MCL), said lead investigator Hun Ju Lee, MD. However, scheduling concerns related to carfilzomib infusions significantly undermine the safety benefit.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication